Caplin Point Laboratories has announced that the transcript of its earnings conference call for the quarter and year ended March 31, 2026, is now available on the company's official website. The call was originally held on Thursday, May 14, 2026, to discuss the financial performance for Q4 and FY2026. This update was communicated via a regulatory filing dated May 21, 2026, signed by Venkatram G, General Counsel & Company Secretary, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Transcript and Audio Access

The transcript of the earnings call has been uploaded to the company's website and can be accessed via the provided link. Additionally, the audio recording of the session remains available for investors, analysts, and fund houses who were unable to participate in the live event.

Earnings Conference Call Details

The conference call covered the company's financial results and business outlook. The following details were relevant to the event:

Management Representatives

The management team represented Caplin Point Laboratories during the call, including the Chairman, Vice Chairman, Managing Director, Chief Financial Officer, and Deputy CFO.

Investor Relations Contact

For queries regarding the earnings conference call, participants may contact the designated investor relations representatives at Churchgate Partners or 360 One CM Research.

Caplin Point Laboratories has announced its ambition to enter a range of new regulated markets as part of its broader global expansion strategy. The company is targeting geographically and regulatorily diverse regions, reflecting a multi-pronged approach to international growth.

Targeted Markets for Expansion

Caplin Point Laboratories has identified several key regulated markets it aims to enter. The following table outlines the regions and market categories the company is looking to penetrate:

A Broader Regulated Market Push

The company's expansion plans span both established regulated markets such as Canada and Australia, as well as high-growth emerging markets including MENA and Russia/CIS. In Latin America, Caplin Point Laboratories is specifically focusing on larger markets — Mexico and Brazil — which represent significant opportunities given their scale and pharmaceutical demand.

This strategic direction underscores the company's intent to diversify its international revenue base by establishing a presence in markets with distinct regulatory frameworks and growth profiles.